Investigating hexose-6-phosphate dehydrogenase in the control of skeletal muscle function and carbohydrate metabolism
Lead Research Organisation:
University of Birmingham
Department Name: Clinical and Experimental Medicine
Abstract
This proposal aims to understand more about the metabolic pathways that mammals use to derive energy from the glucose found in food and utilise it in muscle. Muscle is a vital tissue for controlling body glucose levels, which when elevated can be detrimental. We currently live in a time when glucose and calorie rich food is widely available (the consequences of too much glucose and calories are seen in obesity and diabetes). However, the underlying biological consequences our changing diets has are poorly understood so it is becoming increasingly important to gain a better understanding of the fundamental physiological processes that regulate glucose and energy metabolism in muscle. Our recent work has identified two enzymes in muscle that control important aspects of glucose metabolism. The first enzyme called 11b-HSD1 controls steroid hormone levels, which have potent effects on glucose usage in response to stress. The second enzyme called H6PDH metabolises glucose. What is interesting is that H6PDH can control 11b-HSD1 depending upon the supply of glucose, however, steroid hormones can control glucose levels, highlighting that these enzymes can control each others functions. This interaction between glucose and steroid hormone metabolism is very novel and our recent preliminary findings indicate that it plays an important role, therefore we wish to explain the underlying biology in muscle. To achieve this, we will manipulate H6PDH and 11b-HSD1 levels in muscle to varying degrees (e.g. simultaneously trying to increase steroid hormone metabolism, decrease glucose metabolism) using cells in culture and observe the consequences on cellular metabolism. These experiments will help to guide our use of mice with genetically modified H6PDH and 11b-HSD1 genes, which will allow a true assessment of their roles in a more physiologically relevant system. The experiments will test how steroid hormones and glucose metabolism can be manipulated and derive the true function of these systems in helping to control muscle tissues energy requirements. Ultimately, we hope these basic and fundamental studies will help other scientists, pharmaceutical companies and medical practitioners to improve their scientific knowledge and research. Understanding how energy metabolism is controlled will also aid improvements society's knowledge and hopefully create future health benefits.
Technical Summary
Mammalian carbohydrate homeostasis is of primary importance to energy provision and the action of insulin on metabolism. In muscle, glucose is phosphorylated to glucose-6-phosphate (G6P) and used by multiple pathways including ATP generation. We have identified the enzyme H6PDH, within the sarcoplasmic reticulum (SR) of muscle which can metabolise G6P and may have an important role in its utilisation. One known function of H6PDH is to generate NADPH cofactor which allows the enzyme 11b-HSD1 to produce intracellular glucocorticoids (GCs), hormones that control metabolism by regulating gene transcription. H6PDH knockout mice (H6PDHKO) show the obligate nature of 11b-HSD1 for H6PDH. In the absence of H6PDH, 11b-HSD1 inactivates GCs, leading to blunted responses to GCs. Interestingly H6PDHKO mice also develop a vacuolating myopathy associated with activation of ER stress pathways and alterations in local and global glucose homeostasis. We hypothesise that changes in muscle H6PDH expression can modulate G6P and ATP levels that affect local and whole body metabolism which can be independent of GCs and 11b-HSD1. Aims - Determine the contributions of H6PDH mediated G6P and GC metabolism to glucose homeostasis - Define the contribution of H6PDH G6P metabolism to myopathy and glucose homeostasis in H6PDKO mice - Elucidate the relationship between H6PDH expression in muscle and the ER stress response This study will define the metabolic role of H6PDH in muscle and how it relates to GC metabolism, insulin sensitivity and glucose homeostasis and explore the observations linking aberrant ER metabolism to defective muscle structure and function. The proposed research will determine new and fundamental mechanisms of carbohydrate metabolism in highly relevant systems that have important benefits for our understanding of mammalian metabolic physiology.
People |
ORCID iD |
Gareth Geoffrey Lavery (Principal Investigator) |
Publications
Abrahams L
(2012)
Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11ß-HSD1 and H6PDH.
in The Journal of endocrinology
Bird A
(2017)
Hydroxysteroid dehydrogenase HSD1L is localised to the pituitary-gonadal axis of primates
in Endocrine Connections
Doig CL
(2017)
11ß-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice.
in Endocrinology
Doig CL
(2014)
TNFa-mediated Hsd11b1 binding of NF-?B p65 is associated with suppression of 11ß-HSD1 in muscle.
in The Journal of endocrinology
Doig CL
(2020)
Induction of the nicotinamide riboside kinase NAD+ salvage pathway in a model of sarcoplasmic reticulum dysfunction.
in Skeletal muscle
Fenton CG
(2019)
11ß-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy.
in Arthritis research & therapy
Fenton CG
(2019)
Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis.
in Arthritis research & therapy
Gathercole LL
(2013)
11ß-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.
in Endocrine reviews
Hardy RS
(2018)
11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis.
in Journal of autoimmunity
Hardy RS
(2016)
11ß-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation.
in The Journal of pathology
Description | The major aspects of objectives of the award were met. The award delineated new aspects of muscle energy metabolism and physiology that will inform our understanding of ageing metabolic decline. The award Identified new systems that control muscle function in response to metabolic stress such as in obesity, diabetes, hormonal imbalance or other diseases. Clarified a key mechanism that may explain how an individual may succumb to glucocorticoid excess and suggest a therapeutic option. The award has led to basic laboratory research being translated into clinical trials that have facilitated a better understanding of human physiology in health and disease. The following registered trials are directly attributable to outcomes of this award- - Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)- ClinicalTrials.gov Identifier: NCT03111810 - Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)- ClinicalTrials.gov Identifier: NCT02950441 The award has enhanced our understanding of muscle energy metabolism and supported the generation of data that formed the basis of research support awarded by the Wellcome Trust to continue the theme of the work- focussing on muscle health in ageing. Employability of those funded by the award was enhanced- all post holders going to up take up a postdoctoral position, a tenured Senior Lecturer position and tenured Professor position. |
Exploitation Route | ClinicalTrials.gov- NCT03111810 and ClinicalTrials.gov- NCT02950441 are good evidence of major onward achievements of the award in that basic research finds utility to understand human health and disease. These trials may go on to form the basis for further large scale trials to better tailor treatments for disease. Our follow on funding from the Wellcome Trust supported continued basic discovery science using the full range experimental models- including humans. Clinical researchers are now able to use these discoveries to design clinical in population based studies and interventions. Clinical researchers are also interested in the wider implications of our achievements and tools in defining novel physiology of health and disease across a wider range of conditions, increasing the reach of this fundamental research. Finally, industry is using the achievements of the award to support academic research in areas that could generate therapies. Clinicians may which to use the data and resources we have generated to invest in trials examining the effectiveness of treatment options for Cushing's disease. |
Sectors | Education,Healthcare,Pharmaceuticals and Medical Biotechnology |
Description | Heath and well being treatment potential in a rare disease (Cushing's disease/ syndrome)- if the right centres and researchers wish to take these published findings forward in to clinical research then this could be very beneficial. New knowledge has been generated and can be used as the information base for new science to be conducted.An example is the following entry on ClicnialTrials.gov- Targeting Iatrogenic Cushing's Syndrome With 11ß-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)- ClinicalTrials.gov Identifier: NCT03111810 |
First Year Of Impact | 2017 |
Sector | Education,Healthcare,Pharmaceuticals and Medical Biotechnology |
Impact Types | Societal,Economic |
Description | 1x MRC/University of Birmingham studentships |
Amount | £65,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2013 |
End | 09/2016 |
Description | 2x MRC/University of Birmingham studentships |
Amount | £113,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2010 |
End | 09/2014 |
Description | Exploring beta cell reprogramming by glucocorticoids |
Amount | £187,330 (GBP) |
Funding ID | 17/0005681 |
Organisation | Diabetes UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2018 |
End | 01/2021 |
Description | Pathways Regulating Intramyocellular Insulin Sensitivity and Metabolism in Health and Disease-PRIISM-HD. |
Amount | £186,000 (GBP) |
Organisation | Marie Curie |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2017 |
End | 11/2020 |
Description | Project grant |
Amount | £450,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2013 |
End | 04/2016 |
Description | Project grant |
Amount | £235,000 (GBP) |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2012 |
End | 05/2015 |
Description | Selective CYP11B1 inhibitors as a novel treatment option for endogenous cortisol excess |
Amount | £248,078 (GBP) |
Funding ID | MR/R002339/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2018 |
End | 11/2022 |
Description | The role of CD248 (Endosialin) in adipocyte differentiation and fat formation |
Amount | £425,534 (GBP) |
Organisation | AstraZeneca |
Sector | Private |
Country | United Kingdom |
Start | 04/2019 |
End | 03/2022 |
Description | Wellcome Trust Senior Research Fellowship In Basic Biomedical Sciecne |
Amount | £1,606,529 (GBP) |
Funding ID | 104612/Z/14/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2014 |
End | 10/2019 |
Title | HSD11B1 floxed allele |
Description | Allows the tissue specific inspection of the function of the HSD11B1 gene in mice through genetic recombination methods. |
Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
Year Produced | 2012 |
Provided To Others? | Yes |
Impact | Supported successful grant and personal fellowship application and publications with translational implications for human health |
Description | ChromaDex and Nicotinamide Riboside (NR) MTA |
Organisation | ChromaDex |
Country | United States |
Sector | Private |
PI Contribution | Initiated collaboration as research indicated that Nicotinamide Riboside made by ChromaDex will have an important bearing on our results. We contacted them and we have entered an MTA to be supplied with NR compound. |
Collaborator Contribution | ChromaDex have provided, under an MTA NR compound for use in experiments as described in the MTA. |
Impact | Has supported my research group being funded through the attainment of a Wellcome Trust Senior Research Fellowship- for which ChromaDex were a signed collaborator. |
Start Year | 2013 |
Description | Think tank late night engagement |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Most recently the Lavery lab collaborated with the Thinktank Birmingham Science Museum to be part of a special late-night event that saw over 350 attendees visit the museum 'after hours' to engage with scientists in an approachable and friendly environment. Importantly, this event was free, giving young and old people who might not otherwise engage with science an opportunity to do so as part of an evening mixing science and art. |
Year(s) Of Engagement Activity | 2019 |
URL | https://garethlaverylab.com/explore-our-site/engagement/ |